Vertex Pharma, US92532F1003

Vertex Pharmaceuticals stock: Genomics pact adds four years

Published on 11/21/2026 at 11:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharmaceuticals stock enters the week after a new research alliance with Genomics. The deal targets precision-medicine programs and future drug discovery.

Research partnership strengthens pipeline focus

  • Genomics and Vertex extended their drug target discovery and validation collaboration on November 18.
  • The agreement covers human genetics, biomarker selection and precision-medicine research.
  • The U.S. Food and Drug Administration has set November 30 as the target action date for povetacicept in IgA nephropathy.
Vertex Pharma, US92532F1003, Illustration mit AI erstellt.

Vertex Pharmaceuticals stock traded at 472.10 euros on Lang & Schwarz at 11:11 CET on Saturday, November 21, 2.42 percent below the Xetra close of Wednesday, November 18.

Genomics pact extends research reach

Genomics announced on Wednesday, November 18, that it had extended its strategic drug target discovery and validation collaboration with Vertex Pharmaceuticals for four years. The Genomics press release puts the total potential contract value above 220 million US dollars, including research, development, regulatory and commercial milestones as well as tiered royalties on future net sales.

The partnership builds on eight years of cooperation that began in 2018. The companies plan to use human genetics to identify and validate drug targets, select biomarkers and advance precision medicines. For Vertex, the agreement supports research diversification beyond its established cystic-fibrosis franchise, although the release does not identify specific clinical programs arising from the collaboration.

FDA decision remains a key catalyst

Vertex's broader pipeline also faces a near-term regulatory event. The company said its povetacicept application for IgA nephropathy was under priority review, with a U.S. Food and Drug Administration target action date of November 30, 2026. The application is supported by interim Phase 3 RAINIER data.

On Xetra, the stock's last close in the reporting week was 483.80 euros on Wednesday, November 18, compared with 487.20 euros on Friday, November 13. That produced a weekly decline of 0.70 percent. The current Lang & Schwarz quote places the stock below the most recent Xetra close, while the partnership and the pending FDA decision keep pipeline execution in focus for investors.

Vertex Pharmaceuticals key figures

  • Company: Vertex Pharmaceuticals Incorporated
  • ISIN: US92532F1003
  • Ticker: VRTX
  • Home exchange: Nasdaq
  • Lang & Schwarz quote: 472.10 euros on November 21, 2026, at 11:11 CET
  • Daily comparison: 2.42 percent below the Xetra close of November 18, 2026
  • Weekly Xetra change: From 487.20 euros on November 13 to 483.80 euros on November 18, 2026

Investors can follow broader developments in the Current market reports.

More news and analyses on Vertex Pharmaceuticals stock

Disclaimer...
en | US92532F1003 | VERTEX PHARMA | boerse | 70541963 | bgmi